Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:01pm, Tuesday, 12'th May 2026
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage
11:21pm, Saturday, 09'th May 2026
PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD fran
PTC Therapeutics Q1 Earnings Call Highlights
05:08pm, Friday, 08'th May 2026
PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or P
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
01:51am, Friday, 08'th May 2026
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
07:30pm, Thursday, 07'th May 2026
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Thursday, 07'th May 2026
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 07'th May 2026
– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentu
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
10:15am, Wednesday, 06'th May 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance fo
PTC Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Monday, 04'th May 2026
WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conf
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:01am, Thursday, 30'th Apr 2026
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
02:48pm, Wednesday, 29'th Apr 2026
PTC Therapeutics Inc. (NASDAQ:PTCT) shares are tumbling on Wednesday, after the company reported topline results from the 24-month interim analysis of its PIVOT-HD long-term extension study.
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
04:05pm, Tuesday, 28'th Apr 2026
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
09:28am, Tuesday, 28'th Apr 2026
WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m.
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT
03:14am, Sunday, 26'th Apr 2026
Abacus FCF Advisors LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The insti
